Attorneys general from West Virginia, Ohio, and 42 other states have filed an antitrust lawsuit against 20 of the nation’s largest generic drug manufacturers.
The lawsuit, filed in US District Court in Connecticut, accuses the drugmakers of a conspiracy to “artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade” for more than 100 generic drugs.
“The allegations that we have included in the complaint, when proven, are illegal and those who participated in this type of conspiracy must be held accountable,” West Virginia Attorney General Morrisey said.
“Antitrust violations drive up prices for the consumer and, in this instance, it impacts those in desperate need of prescription drugs.”
Authorities said the drugs at issue account for billions of dollars of sales in the United States and that the alleged schemes increased prices affecting the health-insurance market, health-care programs like Medicare and Medicaid, and individuals who must pay artificially-inflated prices for their prescriptions drugs, Ohio Attorney General Dave Yost said in a news release.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Apple and Amazon Avoid Mass Lawsuit in UK Over Alleged Collusion
Jan 14, 2025 by
CPI
Top Agent Network Drops Antitrust Suit Against National Association of Realtors
Jan 14, 2025 by
CPI
Weil, Gotshal & Manges Strengthens Antitrust Practice with New Partner
Jan 14, 2025 by
CPI
Russian Court Imposes Hefty Fine on Google for Non-Compliance with Content Removal Orders
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand